Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021 by Spaander, Manon C. W. et al.
Esophageal stenting for benign and malignant disease:
European Society of Gastrointestinal Endoscopy (ESGE) Guideline –
Update 2021
Authors
Manon C. W. Spaander1 , Ruben D. van der Bogt1, Todd H. Baron2, David Albers3, Daniel Blero4, Antonella
de Ceglie5 , Massimo Conio6, László Czakó7, Simon Everett8, Juan-Carlos Garcia-Pagán9, Angels Ginès10, Manol
Jovani11 , Alessandro Repici12, 13, Eduardo Rodrigues-Pinto14, Peter D. Siersema15, Lorenzo Fuccio16 , Jeanin E. van
Hooft17
Institutions
 1 Department of Gastroenterology and Hepatology,
Erasmus MC University Medical Center, Rotterdam, The
Netherlands
 2 Department of Internal Medicine, Division of
Gastroenterology and Hepatology, University of North
Carolina, Chapel Hill, North Carolina, USA
 3 Department of Internal Medicine and
Gastroenterology, Elisabeth-Krankenhaus Academic
Hospital, University of Duisburg-Essen, Essen,
Germany
 4 Department of Gastroenterology,
Hepatopancreatology and Digestive Oncology, CUB
Erasme Hospital, ULB (Free University of Brussels),
Brussels, Belgium
 5 Department of Gastroenterology, Ospedale Civile di
Sanremo, Sanremo (IM), Italy
 6 Department of Gastroenterology, Ospedale Santa
Corona, Pietra Ligure (SV), Italy
 7 First Department of Medicine, Faculty of Medicine,
University of Szeged, Szeged, Hungary
 8 Department of Gastroenterology and Hepatology,
Leeds Teaching Hospital NHS Trust, Leeds, UK
 9 Barcelona Hepatic Hemodynamic Laboratory, Liver
Unit – Health Care Provider of the European Reference
Network on Rare Liver Disorders (ERN-Liver) – Hospital
Clinic, IDIBAPS and CIBERehd, University of Barcelona,
Barcelona, Spain
10 Gastroenterology Department, Hospital Clinic of
Barcelona, IDIBAPS and CIBERehd, University of
Barcelona, Barcelona, Spain
11 Department of Gastroenterology and Hepatology,
Johns Hopkins Medical Institutions, Baltimore,
Maryland, USA
12 Endoscopy Unit, IRCCS Istituto Clinico Humanitas,
Rozzano, Milan, Italy
13 Department of Biomedical Sciences, Humanitas
University, Pieve Emanuele, Milan, Italy
14 Gastroenterology Department, Centro Hospitalar São
João, Porto, Portugal
15 Department of Gastroenterology and Hepatology,
Radboud University Medical Center, Nijmegen, The
Netherlands
16 Gastroenterology Unit, Department of Medical and
Surgical Sciences, S. Orsola-Malpighi Hospital,
University of Bologna, Bologna, Italy
17 Department of Gastroenterology and Hepatology,




Endoscopy 2021; 53: 751–762
DOI 10.1055/a-1475-0063
ISSN 0013-726X
© 2021. European Society of Gastrointestinal Endoscopy
All rights reserved.
This article is published by Thieme.
Georg Thieme Verlag KG, Rüdigerstraße 14,
70469 Stuttgart, Germany
Corresponding author
Manon C.W. Spaander, MD, PhD, Department of
Gastroenterology and Hepatology, Erasmus MC University




Supplementary material is available under
https://doi.org/10.1055/a-1475-0063






























Esophageal cancer is the seventh most common cancer type
worldwide, with a global incidence of 604100 new cases in
2020 [1–3]. The main symptoms of esophageal cancer include
dysphagia, with concomitant weight loss and odynophagia [4].
Because patients with esophageal cancer are usually asympto-
matic in the early stages, more than half of patients are diag-
nosed at an advanced stage of the disease and are not eligible
for treatment with curative intent [5].
One of the main goals of palliative treatment is to relieve
dysphagia and improve nutritional intake. A variety of thera-
peutic options are available, including external beam radiation
therapy (EBRT), brachytherapy, and esophageal stent place-
ment. Esophageal stent placement is preferable in patients
with an expected short-term survival because of its rapid relief
of dysphagia symptoms [6]. Different stent designs are avail-
able, varying in stent material (plastic, metal), covering, diame-
ter, and antimigration features. Partially covered self-expand-
able metal stents (PCSEMSs) and fully covered self-expandable
metal stents (FCSEMSs) are most often used in current practice.
In addition to their use for the palliation of dysphagia,
esophageal stents can be used for the treatment of benign
esophageal diseases. Stents are usually removed after several
weeks as this timeframe allows for the resolution of disease
and safe stent removal. FCSEMSs have been mostly used for
the treatment of benign disorders. In recent years, biodegrad-
able stents (BDSs) have gained increasing attention for obviat-
ing the need for stent removal.
This is an update of the clinical guideline on the use of
esophageal stents for benign and malignant disease issued in
MAIN RECOMMENDATIONS
Malignant disease
1 ESGE recommends placement of partially or fully covered
self-expandable metal stents (SEMSs) for palliation of malig-
nant dysphagia over laser therapy, photodynamic therapy,
and esophageal bypass.
Strong recommendation, high quality evidence.
2 ESGE recommends brachytherapy as a valid alternative,
alone or in addition to stenting, in esophageal cancer
patients with malignant dysphagia and expected longer
life expectancy.
Strong recommendation, high quality evidence.
3 ESGE recommends esophageal SEMS placement for seal-
ing malignant tracheoesophageal or bronchoesophageal
fistulas.
Strong recommendation, low quality evidence.
4 ESGE does not recommend SEMS placement as a bridge to
surgery or before preoperative chemoradiotherapy because
it is associated with a high incidence of adverse events.
Other options such as feeding tube placement are prefer-
able.
Strong recommendation, low quality evidence.
Benign disease
5 ESGE recommends against the use of SEMSs as first-line
therapy for the management of benign esophageal stric-
tures because of the potential for adverse events, the avail-
ability of alternative therapies, and their cost.
Strong recommendation, low quality evidence.
6 ESGE suggests consideration of temporary placement of
self-expandable stents for refractory benign esophageal
strictures.
Weak recommendation, moderate quality evidence.
7 ESGE suggests that fully covered SEMSs be preferred over
partially covered SEMSs for the treatment of refractory
benign esophageal strictures because of their very low risk
of embedment and ease of removability.
Weak recommendation, low quality evidence.
8 ESGE recommends the stent-in-stent technique to re-
move partially covered SEMSs that are embedded in the
esophageal wall.
Strong recommendation, low quality evidence.
9 ESGE recommends that temporary stent placement can
be considered for the treatment of leaks, fistulas, and per-
forations. No specific type of stent can be recommended,
and the duration of stenting should be individualized.
Strong recommendation, low quality of evidence.
10 ESGE recommends considering placement of a fully cov-
ered large-diameter SEMS for the treatment of esophageal
variceal bleeding refractory to medical, endoscopic, and/or
radiological therapy, or as initial therapy for patients with
massive bleeding.
Strong recommendation, moderate quality evidence.
SOURCE AND SCOPE
This Guideline is an official statement of the European
Society of Gastrointestinal Endoscopy (ESGE). It provides
guidance on the use of esophageal stents for both malig-
nant and benign conditions. The Grading of Recommen-
dations Assessment, Development, and Evaluation
(GRADE) system was adopted to define the strength of
recommendations and the quality of evidence.





























2016 by the European Society of Gastrointestinal Endoscopy
(ESGE) [7]. In this guideline update, the current evidence will
be discussed and recommendations on the use of esophageal
stents will be provided.
2 Methods
The ESGE Guidelines Committee (chair, J.v.H.) commissioned
this guideline update and appointed a Guideline leader (M.S.).
Key questions (Table 1s, see online-only Supplementary Mate-
rial) were prepared by a coordinating team (M.S., R.v.d.B., L.F.,
T.B., J.v.H.) and were approved by all guideline participants.
Each guideline participant was assigned to a research question
in one of two areas: malignant disease (taskforce leader, L.F.)
and benign disease (taskforce leader, T.B.).
A literature search of MEDLINE and the Cochrane library was
conducted in August 2020 using the PICO structure (where P
stands for population/patient, I for intervention/indicator, C
for comparator/control, and O for outcome). The quality of col-
lected studies was graded according to the Grading Recom-
mendations Assessment, Development and Evaluation
(GRADE) system and retrieved study outcomes were translated
into evidence tables. Evidence tables and proposed guideline
recommendations were collected by the Guideline leader and
circulated 2 weeks before the digital face-to-face meeting held
on 22 October 2020. During the digital face-to-face meeting,
outcomes of the PICOs were discussed and consensus was
reached on guideline recommendations.
In November 2020, a draft was prepared by M.S. and R.v.d.B.
and sent to the guideline team. The revised draft was reviewed
by two independent experts. After adjustment and final ap-
proval by the guideline team, the manuscript was submitted
for publication by Endoscopy.
This Guideline was issued in 2021 and will again be consid-
ered for updating in 2025.
3 Malignant disorders
3.1 Efficacy
Several randomized controlled trials (RCTs) have compared
the outcomes of esophageal stent placement with other treat-
ment strategies for the palliation of malignant dysphagia due
to esophageal cancer (Table 2s). Laser therapy, photodynamic
therapy, and esophageal bypass surgery have shown compar-
able outcomes to esophageal stent placement [8–13].
Based on two RCTs comparing the outcomes of self-
expandable metal stent (SEMS) placement versus brachyther-
apy, brachytherapy may be considered over SEMS placement
in patients with expected long-term survival [14, 15]. Even
though SEMS placement leads to a more rapid relief of dyspha-
gia, brachytherapy is preferable in these patients for its durable
relief of symptoms [15, 16]. Furthermore, the use of brachy-
therapy is associated with a lower risk of serious adverse events
and favorable quality of life outcomes [14, 15]. Despite these
benefits, the availability of brachytherapy in daily practice is re-
stricted by the need for local expertise and dedicated logistics
RECOMMENDATION
ESGE recommends placement of partially or fully covered
self-expandable metal stents (SEMSs) for palliation of
malignant dysphagia over laser therapy, photodynamic
therapy, and esophageal bypass.
Strong recommendation, high quality evidence.
RECOMMENDATION
ESGE recommends brachytherapy as a valid alternative,
alone or in addition to stenting, in esophageal cancer
patients with malignant dysphagia and expected longer
life expectancy.
Strong recommendation, high quality evidence.
RECOMMENDATION
ESGE recommends patient characteristics be taken into
account when selecting patients for esophageal stent
placement as a palliative method.
Strong recommendation, low quality evidence.
RECOMMENDATION
ESGE recommends against the placement of nonexpand-
able and expandable plastic stents for the palliation of
malignant esophageal strictures.





EBRT external beam radiation therapy
ECOG Eastern Cooperative Oncology Group
ESGE European Society of Gastrointestinal Endos-
copy
ESPEN European Society of Parenteral and Enteral
Nutrition
FCSEMS fully covered self-expandable metal stent
GRADE Grading of Recommendations Assessment,
Development and Evaluation
LAMS lumen-apposing metal stent
OD odds ratio
PCSEMS partially covered self-expandable metal stent
RBES refractory benign esophageal stricture
RCT randomized controlled trial
SEMS self-expandable metal stent
SEPS self-expandable plastic stent
TIPS transjugular intrahepatic portosystemic
shunting




























[17]. A short course of EBRT may be a valid alternative to bra-
chytherapy [18]. In patients with a good performance status,
chemoradiotherapy can be considered to prolong dysphagia-
free survival, but is associated with an increased toxicity com-
pared with radiotherapy alone [19].
Esophageal stent placement is indicated in patients with an
expected short-term survival (i. e. less than 3 months) for its
rapid relief of symptoms, usually within 1–2 days after stent
placement [6]. Several prognostic tools may aid the selection
of esophageal stent candidates, but these lack external valida-
tion [20–22]. The presence of metastases and poor perform-
ance status have repeatedly been shown to be associated with
poor survival [21–24]. When esophageal stent placement is
considered, SEMSs are recommended over self-expandable
plastic stents (SEPSs) owing to a lower rate of symptom recur-
rence and serious adverse events [6]. To date, there have been
no differences shown in the outcomes of FCSEMS and PCSEMS
placement, or the placement of SEMSs with or without an anti-
reflux mechanism [25–28].
3.2 Safety
In the previous ESGE guideline, a meta-analysis of the available
evidence was performed for the occurrence of stent-related
adverse events [7]. The major adverse event rate was reported
to be 21% for FCSEMSs and 18% for PCSEMSs. The most fre-
quent early adverse events were reflux (9.3%), severe pain
(8.7%), and bleeding (7.6%). The most frequent late adverse
events were reflux (15%), severe pain (15%), and ingrowth/
overgrowth (14%).
In recent years, an increase in stent-related adverse events
has been reported, which has been attributed to the increased
use of chemotherapy and/or radiotherapy before SEMS place-
ment [29]. Other patient characteristics that appear to be asso-
ciated with an increased risk of adverse events include female
sex and dilation before SEMS placement [28, 29].
3.3 Fistula
The incidence of esophageal fistulas has increased markedly
as a result of advances in palliative therapies for esophageal
cancer [30, 31]. Esophageal fistulas usually occur in the context
of advanced esophageal cancer, but may also result from other
malignancies or prior (palliative) therapy [30–34]. The symp-
toms of an esophageal fistula include cough, fever, and pneu-
monia [35]. Because the development of an esophageal fistula
is considered to be an indicator of poor survival (weeks to
months), treatment strategies should aim to rapidly relieve
symptoms and improve the patient’s remaining quality of life.
The clinical success rate of SEMS placement for malignant
fistulas ranges between 56% and 100% [35–44]. Factors asso-
ciated with treatment failure include proximal fistula location,
fistula orifice size > 1 cm, and Eastern Cooperative Oncology
Group (ECOG) performance status of 3–4 [42, 43]. After the fis-
tula has been successfully sealed, reopening occurs in 0–39% of
patients [39–42]. In most cases, reopening can be managed
endoscopically by repositioning the SEMS or by placement of
an additional SEMS [41, 42]. Airway stenting may be considered
in addition to esophageal SEMS placement to improve the suc-
cess rate and prevent airway obstruction [44–47].
The outcomes of SEMS placement have been compared with
other treatment strategies in two retrospective studies [37,
38]. Chen et al. reported on the outcomes of SEMS placement
(n =30) versus feeding gastrostomy/jejunostomy (n=35) and
found SEMS placement to be associated with an improved over-
all survival [37]. In a study by Hu et al., the outcomes of SEMS
placement (n =17) were compared with gastrostomy (n=9) and
best supportive care (n =9) [38]. The median survival was com-
parable among the treatment arms. Patients who underwent
SEMS placement had favorable quality of life outcomes on sev-
eral subscales, including eating and respiratory problems.
3.4 Bridge to surgery
Neoadjuvant therapy followed by surgery is the current clin-
ical standard for treatment with curative intent for esophageal
cancer [48, 49]. Malnutrition and cachexia – common in esoph-
ageal cancer patients – are known risk factors for treatment-
related adverse events and poor survival [50–52]. From this
perspective, the European Society of Parenteral and Enteral Nu-
trition (ESPEN) recommends regular assessment of a patient’s
nutritional status [53]. Initial screening can be performed by
assessment of nutritional intake, weight change, and body
mass index. Nutritional support is strongly recommended for
patients at severe nutritional risk, defined as more than 10%–
15% weight loss in the previous 6 months [54, 55].
RECOMMENDATION
ESGE recommends esophageal SEMS placement for seal-
ing malignant tracheoesophageal or bronchoesophageal
fistulas.
Strong recommendation, low quality evidence.
RECOMMENDATION
ESGE recommends the application of double stenting
(esophagus and airway) when fistula occlusion is not
achieved by esophageal or airway prosthesis placement
alone.
Strong recommendation, low quality evidence.
RECOMMENDATION
ESGE does not recommend SEMS placement as a bridge
to surgery or before preoperative chemoradiotherapy be-
cause it is associated with a high incidence of adverse
events. Other options such as feeding tube placement
are preferable.
Strong recommendation, low quality evidence.





























Esophageal stents have been used to improve nutritional sta-
tus before neoadjuvant therapy and surgery. In a meta-analysis
of nine studies (5 SEPS, 3 SEMS, 1 SEPS+SEMS), the outcomes
of 180 patients undergoing stent placement prior to or during
neoadjuvant therapy were pooled [56]. Stent placement was
technically successful in 95% of patients, with a statistically sig-
nificant improvement in dysphagia symptoms, but without im-
provement in weight or serum albumin levels. Stent migration
and chest discomfort occurred in 32% and 51% of patients,
respectively. The relatively high rate of stent migration in this
setting has been attributed to neoadjuvant therapy-induced
tumor shrinkage, as most of these patients do not require
repeated intervention [56, 57]. To overcome the substantial
risk of adverse events, van den Berg et al. investigated the out-
comes of BDS placement in 10 patients scheduled to undergo
neoadjuvant chemoradiotherapy [58]. A statistically significant
decrease in dysphagia symptoms occurred without any major
adverse events. Nevertheless, 7 of 10 patients required addi-
tional nutritional support and median weight loss before sur-
gery was 5.4 kg.
In the past, SEMS placement before surgery has been report-
ed to be associated with a worse oncologic outcome with a low-
er rate of R0 resections, a higher rate of major adverse events,
and decreased overall survival [59, 60]. Contrarily, recent stud-
ies have reported no difference in R0 resection rate, overall sur-
vival, and postoperative complications [61–63].
Alternatives to esophageal stent placement include oral nu-
tritional supplements, nasogastric tube placement, percutan-
eous feeding tube placement, and parenteral nutrition. In gen-
eral, the use of percutaneous feeding tube placement (i. e. per-
cutaneous endoscopic gastrostomy or endoscopic jejunost-
omy) is recommended when enteral feeding is expected to be
continued for at least 4 weeks [64–66]. In surgical candidates,
percutaneous endoscopic gastrostomy is considered by some
surgical teams to be a contraindication as it may compromise
the construction of a gastric conduit created during distal
esophageal/proximal stomach reconstruction.
3.5 Combined approach
To improve the outcome of stent placement, the use of
radiotherapy in addition to SEMS placement has been investiga-
ted. This combined approach may potentially lead to prolonged
dysphagia relief and improved overall survival [67–70]. Never-
theless, a high risk of major adverse events has been reported
for the combination of EBRT and stent placement, suggesting
stent placement is better reserved for patients who have failed
prior radiotherapy [71].
In contrast to EBRT, the combination of single-dose brachy-
therapy and SEMS placement is safe and effective [67]. The use
of irradiated SEMSs has been a topic of interest that potentially
provides an advantage of combining the benefits of SEMS
placement and brachytherapy. Based on a meta-analysis of six
RCTs, the use of irradiated SEMSs led to an increased dyspha-
gia-free time compared with traditional SEMSs, without affect-
ing the rate of adverse events [72]. To date, however, all of
these studies have been performed in Chinese populations,
thereby warranting (prospective) evaluation in Western popu-
lations.
Only one study has investigated the outcomes of single-dose
brachytherapy in addition to BDS placement [68]. Although
satisfactory relief of symptoms was achieved, an unacceptably
high rate of major adverse events was observed, which necessi-
tated premature study termination.
3.6 Prior palliative therapy
In patients with recurrent dysphagia after first-line palliative
radiotherapy, SEMS placement is considered the main treat-
ment [73]. However, the association between prior palliative
therapy and stent-related adverse events remains controver-
sial. Several studies have reported that prior chemotherapy
and/or radiotherapy increase the risk of life-threatening ad-
verse events after SEMS placement, whereas other studies
have shown the risk of adverse events to be unaffected [29,
34, 74–82]. Pneumonia, fistula formation, and stent-related
pain may be increased in patients with prior therapy who re-
ceive stents [29, 34, 80–82].
The increased risk of adverse events has been explained by
pulmonary toxicity and radiation-induced changes, which in-
crease the susceptibility to pressure necrosis [29, 79, 81–85].
The potential role of radiotherapy-induced changes is suppor-
ted by the increase in the rate of adverse events with a cor-
responding increase in radiation dosage [82, 83]. Regardless,
the increased adverse event rate may also be partially explained
by advanced disease stage, which is known to be related to an
increased risk of life-threatening bleeding and fistula formation
[34, 79].
4 Benign disease
4.1 Refractory benign esophageal strictures
RECOMMENDATION
ESGE does not recommend the concurrent use of radio-
therapy if an esophageal stent is present.
Strong recommendation, low quality evidence.
RECOMMENDATION
ESGE suggests that SEMS placement with concurrent
single-dose brachytherapy is safe and effective for relief
of dysphagia.
Weak recommendation, low quality evidence.
RECOMMENDATION
ESGE recommends against the use of SEMSs as first-line
therapy for the management of benign esophageal stric-
tures because of the potential for adverse events, the
availability of alternative therapies, and their cost.
Strong recommendation, low quality evidence.




























The use of esophageal stents for the treatment of benign
esophageal strictures has mainly been investigated in the con-
text of refractory or recurrent benign esophageal strictures
(RBESs; Table 3s). As defined by Kochman et al., these patients
either fail to reach a target diameter of 14mm after biweekly
dilations over 5 weeks or fail to maintain the target diameter
up to 4 weeks after the last dilation [86]. Esophageal stent
placement has a potential benefit because of its continuous ex-
pansion force, which may lead to stricture remodeling. Al-
though stent placement has not been compared with dilation
in treatment-naïve patients, it is generally accepted that esoph-
ageal stent placement should only be considered as a second-
line approach owing to its relatively high rate of adverse events
and its cost.
In a recent meta-analysis, the outcomes of 18 studies with a
total of 444 patients were pooled [87]. The clinical success rate
after stent placement was 40.5% (95% confidence interval [CI]
31.5%–49.5%). Stent migration was the most common stent-
related adverse event, occurring in 28.6% (95%CI 21.9%–
37.1%). Other adverse events occurred in 20.6% (95%CI
15.3%–28.1%). Treatment outcomes did not differ among the
SEMS, SEPS, and BDS groups.
To reduce the risk of SEMS migration, endoscopic stent fixa-
tion by endoscopic suturing or over-the-stent clips has been in-
vestigated (Table 4s). In general, endoscopic stent fixation is
highly successful (96.7%; 95%CI 92.3%–98.6%) and safe (pro-
cedure-related adverse events, 3.7%; 95%CI 1.6%–8.2%) [88].
In the largest study of RBES patients, endoscopic suturing of
the FCSEMS led to a reduction in stent migration rate compared
with no suturing (9.4% vs. 39.5%; P=0.01) [89]. It remains un-
clear if there is a benefit of routine stent fixation, and it may be
considered in patients with prior stent migration.
Another method to reduce the risk of stent migration is the
use of lumen-apposing metal stents (LAMSs). It is believed that
the typical wide flanges and short lengths of LAMSs may pre-
vent stent migration. To date, LAMSs have only been investiga-
ted in mixed study populations restricted by small sample sizes
[90–94]. More studies are needed to evaluate their potential
benefit in RBES patients.
4.1.1 Factors predicting successful treatment
The current literature provides some evidence that patient
characteristics affect outcomes following stent placement in
RBES patients. The previously mentioned meta-analysis showed
a tendency toward a higher clinical success rate in studies that
included a larger proportion of patients with radiotherapy-
induced strictures and anastomotic strictures [87]. A similar
trend was observed for the risk of stent-related adverse events,
with the risk seeming to be lower in anastomotic strictures
compared with other etiologies. In addition to stricture etiolo-
gy, cervical stricture location and increasing stricture length
have been reported to be associated with lower clinical success
rates [95–97]. Because most studies do not take into account
patient characteristics when reporting study outcomes, their
specific impact remains unclear.
The optimal stent duration for the management of RBES
patients has not been formally tested. It is recommended that
stents remain in place for at least 6–8 weeks, but not longer
than 10–12 weeks after stent placement. It is believed that
this stent duration provides sufficient time to induce stricture
remodeling and at the same time prevents stent embedment.
One retrospective study investigated the influence of stent
duration on the safety of stent removal but found no such asso-
ciation [98]. Stent design was the only independent predictor
RECOMMENDATION
ESGE suggests consideration of temporary placement of
self-expandable stents for refractory benign esophageal
strictures.
Weak recommendation, moderate quality evidence.
RECOMMENDATION
ESGE suggests that fully covered SEMS fixation by endo-
scopic suturing or over-the-scope clips be considered in
patients with previous stent migration.
Weak recommendation, low quality evidence.
RECOMMENDATION
ESGE does not recommend permanent stent placement
for refractory benign esophageal stricture; stents should
usually be removed at a maximum of 3 months following
insertion.
Strong recommendation, low quality evidence.
RECOMMENDATION
ESGE suggests that fully covered SEMSs be preferred over
partially covered SEMSs for the treatment of refractory
benign esophageal strictures because of their very low
risk of embedment and ease of removability.
Weak recommendation, low quality evidence.
RECOMMENDATION
ESGE does not recommend the use of biodegradable
stents over SEMSs in the treatment of benign esophageal
strictures.
Strong recommendation, low quality evidence.
RECOMMENDATION
ESGE recommends the stent-in-stent technique to re-
move partially covered SEMSs that are embedded in the
esophageal wall.
Strong recommendation, low quality evidence.





























of complicated stent removal. Adverse events were more com-
mon with PCSEMSs (odds ratio [OR] 8.83; 95%CI 3.29–23.70)
and SEPSs (OR 4.71; 95%CI 1.39–15.97) when compared with
FCSEMSs. The use of BDSs has been suggested to obviate stent
removal, but compelling evidence for BDSs over other stent
types is lacking [96, 99].
Different methods for endoscopic removal of an embedded
PCSEMS have been described [100–106]. Most studies have re-
ported on the use of the stent-in-stent technique, which relies
on the placement of an additional FCSEMS fully overlapping the
location of the embedded PCSEMS. To induce pressure necro-
sis, the stent diameter of the additional FCSEMS should be at
least that of the embedded PCSEMS. In > 90% of patients, both
SEMSs can be safely removed 10–14 days after placement of
the additional FCSEMS [100, 101]. If removal of the embedded
PCSEMS is unsuccessful, the stent-in-stent technique can be re-
attempted.
4.1.2 Combined approach
Concurrent endoscopic incisional therapy, corticosteroid
injection, and mitomycin-C application are reported to
enhance treatment outcomes of endoscopic dilation therapy.
Data on the use of these endoscopic interventions in combina-
tion with esophageal stent placement are scarce. Only one
study has reported on the outcomes of corticosteroid injection
in combination with FCSEMS placement but no clear benefit
was found [107].
4.1.3 Options after stent failure
In patients with recurrent dysphagia after stent placement,
repeated esophageal stent placement may be considered, but
has not been shown to have significant incremental benefit
[108, 109]. When repeat esophageal stent placement does not
lead to satisfactory results, alternative treatment strategies
should be considered. Surgical treatment represents a valid op-
tion in selected patients, depending on the stricture location
and patient performance status. Furthermore, self-dilation is
safe and effective in the majority of patients [110–112]. Treat-
ment success with self-dilation relies on patient compliance,
restricting its use to self-motivated patients and poor surgical
candidates.
4.2 Leaks, fistulas, and perforations
Esophageal stents are increasingly used in the management
of esophageal perforations [113]. Based on three systematic re-
views on the use of PCSEMSs, FCSEMSs, and SEPSs in anastomo-
tic leaks and perforations, the clinical success rate of esopha-
geal stent placement is 81%–87%, with no difference among
the stent types [114–116]. Even though the clinical success
rates are comparable, SEMSs are reported to perform better
than SEPSs in leaks and perforations, with higher technical
success (95% vs. 91%; P =0.03), and reduced risk of migration
(16% vs. 24%; P=0.001) and stent repositioning (3% vs. 11%;
P<0.001), as well as a reduced risk of perforation when consid-
ering anastomotic leaks only (0% vs. 2%; P=0.01) [116]. Data
on the use of BDSs in these patients are restricted to a few
small retrospective studies (Table 5s) [117–119].
To identify patients who may benefit from esophageal stent
placement, van Halsema et al. developed a clinical prediction
RECOMMENDATION
ESGE suggests that a combined approach of stent place-
ment with additional techniques (e. g. corticosteroid
injection, chemotherapeutic topical application) should
not be undertaken in an attempt to improve the long-
term benefit of temporary stenting.
Weak recommendation, very low quality evidence.
RECOMMENDATION
ESGE suggests alternative treatment strategies such as
self-dilation or surgical treatment for patients with re-
fractory benign esophageal strictures that have not satis-
factorily improved after two separate treatments with
temporary stenting.
Weak recommendation, low quality evidence.
RECOMMENDATION
In poor surgical candidates, ESGE recommends self-
dilation with rigid dilators.
Strong recommendation, low quality evidence.
RECOMMENDATION
ESGE recommends that temporary stent placement can
be considered for the treatment of leaks, fistulas, and
perforations. No specific type of stent can be recommen-
ded, and the duration of stenting should be individual-
ized.
Strong recommendation, low quality of evidence.
RECOMMENDATION
ESGE recommends esophageal stents be placed as early
as possible for the treatment of leaks, fistulas, and per-
forations.
Strong recommendation, moderate quality evidence.
RECOMMENDATION
ESGE recommends including stent placement in a multi-
modality treatment protocol for leaks, fistulas, and per-
forations to optimize the healing success rate and mini-
mize the risk of adverse events.
Strong recommendation, low quality evidence.




























rule based on four clinical parameters: etiology (leak, fistula,
perforation), location, orifice size, and C-reactive protein (CRP)
level [120]. In the validation cohort, the sensitivity and specifi-
city for a 70% predicted probability of clinical success were 33%
and 89%, respectively. Multivariable logistic regression showed
fistulas and orifice size of > 2 cm to be associated with a lower
rate of clinical success. The observed difference between ana-
stomotic leaks and fistulas emphasizes that leaks, fistulas, and
perforations are different entities and may require an individual
approach. For instance, in fistula patients, SEMS placement is
usually performed in combination with other therapies and a
longer stent duration may be needed in anastomotic leaks
compared with perforations [121, 122]. Nevertheless, the cur-
rent literature provides insufficient data to formulate separate
recommendations.
No study has investigated the optimal stent duration. Stents
are usually removed 6–8 weeks after insertion and repeated
stent placement is needed in 11% of patients [114–116]. In
patients who are endoscopically treated for benign esophageal
perforations, early diagnosis (< 24 hours) has been shown to be
associated with a lower need for re-intervention and intensive
care admission, and a shorter hospital stay [123].
Recently, the outcomes of SEMS placement have been com-
pared with endoscopic vacuum therapy for the treatment of
post-surgical leaks [124]. The use of endoscopic vacuum ther-
apy was associated with a higher leak closure rate, more endo-
scopic device changes, shorter duration of treatment, and
lower in-hospital mortality. Because the management of these
patients may be challenging and often requires a multimodality
approach, esophageal stent placement may still be considered
in addition to other endoscopic techniques to optimize treat-
ment outcomes [119].
4.2.1 Safety
Stent migration is the most common stent-related adverse
event and tends to be higher when FCSEMSs (26%) and SEPSs
are used (31%) compared with PCSEMSs (12%) [114]. The use
of large-diameter SEMSs has been suggested to reduce the risk
of stent migration in anastomotic leaks [119]. Furthermore, su-
turing of FCSEMSs may render migration rates similar to those
of PCSEMSs, without the difficulties associated with the remov-
al of PCSEMSs and with a lower risk of adverse events [125].
Other stent-related adverse events include the development of
a stricture, stent erosion, perforation, and bleeding [114–116].
Repeated endoscopic intervention is needed in 17%–25% of
patients and 7%–13% require surgical intervention [114–116].
4.3 Acute variceal bleeding
Esophageal stent placement for acute variceal bleeding has
mainly been investigated in small retrospective studies using a
dedicated stent design (SX-ELLA stent DANIS) for the treatment
of refractory bleeding (Table 6s). Stent duration is reported to
range from 1–30 days [126]. Pooled data analysis shows that
SEMS placement leads to control of bleeding in >80% of
patients, without severe stent-related adverse events [126,
127]. In 21% of patients, bleeding reoccurs within 6 weeks after
SEMS placement [128]. Only one RCT has performed a direct
comparison of SEMSs and balloon tamponade [129]. In this
study of 28 patients, SEMS placement led to a higher rate of
control of bleeding during the first 15 days (85% vs. 47%; P=
0.04) and a lower rate of adverse events (31% vs. 73%; P=0.02).
Despite its effectiveness, the 30-day mortality rate after
SEMS placement may be as high as 36%, also reflecting the se-
verity of the underlying condition [127]. Accordingly, SEMSs
have been proposed as a bridge to transjugular intrahepatic
portosystemic shunting (TIPS) or liver transplantation.
Disclaimer
The legal disclaimer for ESGE guidelines [130] applies to this
Guideline.
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